Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pfizer's Chantix Warning May Remain As FDA Raises Trial Concerns

Executive Summary

FDA will present concerns on data collection and study conduct during advisory committee meeting on removing smoking cessation drug's boxed warning.


Related Content

Chantix's Boxed Warning: Will A Positive Vote Justify A Negative Outcome?
Was FDA Nit-Picking In Criticism Of Pfizer's EAGLES Trial?
Removing Pfizer's Chantix Boxed Warning A One-Off, Committee Says
FDA’s Black Box Instant Replay: A Higher Standard To Remove
Pfizer’s Effort To Remove Chantix Boxed Warning May Backfire
FDA Reviewing Chantix Postmarketing Data On Suicide, Erratic Behavior


Related Companies